Table 3.
List of antibodies used as capture antibodies bound to the polystyrene particles in the multiplex platform [24–27].
| Capture antibody | Clone | Target |
|---|---|---|
| mIgG1 | IS5-21F5 | Isotype control |
| REA | REA293 | Isotype control |
| CD9 | SN4 | Extracellular Vesicle marker |
| CD63 | H5C6 | Extracellular Vesicle marker |
| CD81 | 5A6 | Extracellular Vesicle marker |
| CD1c | AD5-8E7 | BDCA-1, major subpopulation of human myeloid dendritic cells |
| CD2 | LT2.2 | T cells, subset of NK cells |
| CD3 | BW 264/56 | mature human T cells, thymocytes, subset of NK cells |
| CD4 | Vit-4.3 | T helper cells, thymocytes, monocytes, dendritic cells |
| CD8 | BW 135/80 | cytotoxic T cells, thymocytes, subset of NK cells |
| CD11c | MJ4-27G12 | integrin αX or CR4, monocytes, macrophages, NK cells, granulocytes, myeloid dendritic cells (MDCs), subsets of T and B cells |
| CD14 | TÜK4 | monocytes and macrophages, subset of neutrophils and myeloid dendritic cells |
| CD19 | LT-19 | B cells |
| CD20 | LT20.34 | B lineage cells from the pre-B cell stage to the B cell lymphoblast stage |
| CD24 | 32D12 | heat-stable antigen (HSA) |
| CD25 | 3G10 | activated T and B cells, macrophages, subset of non-activated CD4+ regulatory T cells |
| CD29 | TS2/16.2.1 | integrin beta 1 |
| CD31 | AC128 | monocytes, platelets, and granulocytes |
| CD40 | HB14 | B cells, macrophages, dendritic cells, endothelial cells, fibroblasts, plasma cells, subset of peripheral T cells |
| CD41b | REA336 | β chain of Integrin α-IIb, megakaryocytes, platelets |
| CD42a | REA209 | Platelets, megakaryocytes |
| CD44 | DB105 | Cancer stem cells (CSC), hematopoietic, fibroblastic, and glial cells. |
| CD45 | 5B1 | leukocyte common antigen |
| CD49e | NKI-SAM1 | integrin α5 chain, lymphocytes, monocytes, fibroblasts, endothelial cells |
| CD56 | REA196 | neural cell adhesion molecule (NCAM), resting and activated NK cells, minor subset of CD3+ T cells |
| CD62P | REA389 | P-selectin, vascular endothelial cells and platelets |
| CD69 | FN50 | Activated lymphocytes, monocytes, and platelets |
| CD86 | FM95 | B7-2, activated B and T cells, dendritic cells, and monocytes/macrophages |
| CD105 | 43A4E1.71 | mature endothelial cells, some leukemic cells of B lymphoid and myeloid origin |
| CD133 | AC133.1.6. 2.1.1 | multipotent progenitor cells, including immature hematopoietic stem and progenitor cells, circulating endothelial progenitor cells, fetal neural stem cells, other tissue-specific stem cells, cancer stem cells |
| CD142 | HTF-1 | Tissue factor, activated endothelial cells, monocytes, macrophages, platelets, and some tumor cell types |
| CD146 | 541-10B2 | MUC18, MCAM, Mel-CAM, endothelial cells, pericytes, smooth muscle cells, follicular dendritic cells, melanoma cells, sub-population of activated T lymphocytes, marrow stromal cells (MSCs) |
| CD209 | DCN-47.5.4 | DC-SIGN, dendritic cells, endothelial cells, macrophages, spleen |
| CD326 | HEA125 | EpCAM, basolateral surface of carcinoma and epithelial cells in tissues, circulating tumor cells, cancer stem cells, not on melanoma, neuroblastoma, sarcoma, lymphoma, leukemia cells, or normal fibroblasts |
| HLA-ABC | REA230 | Nuclear cells |
| HLADP/DQ/D R | REA332 | Antigen-presenting cells |
| MCSP | EP-1 | melanoma-associated chondroitin sulfate proteoglycan antigen, melanoma tissues and melanoma cell lines but not carcinoma cells, fibroblastoid cells, and cells of hematopoietic origin |
| ROR1 | 2A2 | receptor tyrosine kinase-like orphan receptor 1, chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (McLellan), ovarian cancer, renal cancer, melanoma, and lung adenocarcinoma, adipose tissue, at early stages of B cell development |
| SSEA-4 | Stage-specific embryonic antigen 4, undifferentiated human embryonic stem (ES) cells, induced pluripotent (iPS) cells embryonal carcinoma (EC) cells, and embryonic germ (EG) cells, somatic stem cells |